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CASE STUDY
Heparin-induced thrombocytopenia in a 
non-heparin-naive patient: a case report
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Abstract 
Introduction: Administration of low molecular weight heparin (LMWH) is recommended for prophylaxis of venous 
thromboembolism in patients undergoing hip surgery. In this context, heparin-induced thrombocytopenia (HIT) type 
II is a complication of rare incidence but sometimes fatal outcome.
Case description: A 52-year old obese patient undergoing antithrombotic therapy with Enoxaparin after hip surgery 
presented with a painful, swollen leg and thrombocytopenia on day eight after surgery. Medical history showed pre-
vious administration of Enoxaparin without complications 2 years ago. Further diagnostic investigation supplied evi-
dence of multiple thromboembolic events and concomitant compartment syndrome. Administration of Enoxaparin  
was stopped immediately and treatment with Argatroban was initiated. Diagnosis of HIT was confirmed according to 
current guidelines. Despite interventional thrombectomy and fasciotomy, amputation of both lower limbs had to be 
performed due to ongoing necroses. After a 30-days-stay at the intensive care unit because of sepsis, respiratory and 
renal failure, clinical condition improved and the patient could be transferred for rehabilitation.
Discussion and evaluation: HIT II is known as complication of administration of LMWH in the perioperative setting. 
Diagnosis results from clinical findings and platelet count. Argatroban is recommended as an alternative therapeutic 
anticoagulant in HIT II. Inflammation and surgical trauma are discussed as priming factors to increase risk of HIT II.
Conclusions: Administration of LMWH may result in HIT II despite prior uneventful drug exposure. Except for imme-
diate diagnosis, only consequent anticoagulation can stop the course of disease. Hence, interdisciplinary awareness is 
inevitable for early diagnosis and accurate therapy to prevent from a catastrophic clinical course.
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Introduction
Administration of low molecular weight heparin 
(LMWH) is recommended for prophylaxis of venous 
thromboembolism (VTE) in patients undergoing hip 
surgery (Falck-Ytter et al. 2012). In this context, heparin-
induced thrombocytopenia (HIT) type II is a well-known, 
immune-mediated complication of rare incidence 
(1–6.5  % in orthopaedic patients, depending on type of 
heparin), but sometimes fatal outcome (Linkins et  al. 
2012; Girolami and Girolami 2006; Picker and Gathof 
2004).
Risk factors—among others—include type of patient 
population. Especially cardiac and orthopaedic surgery 
is related to a higher incidence of HIT II (Dasararaju 
et  al. 2013; Linkins et  al. 2012). Warkentin et  al. (2000) 
concluded: HIT-IgG antibodies are more likely to form 
in patients who undergo cardiac surgery than in ortho-
paedic patients, but among patients in whom antibodies 
do form, orthopaedic patients are more likely to develop 
HIT. Inflammation and surgical trauma are discussed 
as priming factors to increase the risk of HIT II (Krauel 
et al. 2012; Lubenow et al. 2010).
Diagnosis of HIT results from clinical findings and 
platelet count (Dasararaju et al. 2013; Linkins et al. 2012). 
Once HIT II is suspected, administration of LMWH has 
to be stopped without delay and an alternative therapeu-
tic anticoagulant has to be initiated (Linkins et al. 2012). 
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Progressive thrombocytopenia results from intravascu-
lar platelet activation. The magnitude of thrombocyto-
penia correlates with thrombotic risk (Greinacher et  al. 
2010). An increase in platelet count on the other hand 
represents effective therapeutic anticoagulation as it 
reflects the breakdown of platelets’ consumption within 
the thrombus. In contrast, substitution of platelet con-
centrates and heparin-like substances—which are nota-
bly included in most coagulation factor concentrates as 
well—can worsen the prognosis.
The absence of pathological findings within the 
patient`s medical history does not ensure that re-admin-
istration of LMWH may not result in HIT II. However, 
patients with heparin exposure within the last 100  days 
show an early onset (<5  days) of thrombocytopenia 
whereas if LMWH have been administered more than 
3  months ago, the onset of thrombocytopenia seems to 
be indistinguishable from patients having had their initial 
exposure to heparin (typically day 5–10) (Lubenow et al. 
2002; Dasararaju et al. 2013).
This article aims to emphasize, that except for imme-
diate diagnosis, only consequent therapeutic anti-
coagulation can stop the course of disease. Hence, 
interdisciplinary awareness is inevitable for early diagno-
sis and accurate therapy to prevent from a catastrophic 
clinical course.
Case description
A male 52-year-old patient (body mass index 43 U) 
undergoing antithrombotic therapy with Enoxaparin 
(Lovenox®) after hip surgery presented with ongoing 
pain, a swollen leg and isolated necrotic spots on day 
eight after surgery. Medical history revealed previous 
uneventful administration of Enoxaparin 2  years ago. 
Despite from normal platelet count (286G/l) at the begin-
ning of LMWH therapy, standard laboratory parameters 
now showed a new onset of thrombocytopenia (33 G/l). 
Clinical state, results of ultrasound of the lower limb 
and a CT-angiography supplied evidence of a major 
thromboembolic event within the right arteria femoralis 
superficialis and concomitant compartment syndrome. 
Administration of Enoxaparin was stopped immediately 
and treatment with Argatroban (Argatra®) was initiated. 
According to the 4T’s score (8 points) and the detection 
of PF4-heparin antibodies via an ELISA immunoassay, 
HIT diagnosis was likely and finally confirmed with hep-
arin-induced platelet aggregation assay (HIPAA).
Despite interventional thrombectomy and fasciotomy, 
amputation of the left leg had to be performed 2  days 
later. On day 15 after hip surgery, thrombosis of the right 
vena poplitea and vena femoralis superficialis required 
interventional thrombectomy and fasciotomy. However, 
this did not prevent from amputation because of ongoing 
necrosis of the right lower limb (Fig.  1). Acral necrotic 
spots indicated microembolism (Fig.  2). Due to septic 
shock the patient developed acute kidney failure and 
citrate-dialysis had to be performed. Furthermore, it took 
dilatative tracheotomy in order to facilitate respiratory 
weaning.
Throughout a 30-days stay at the intensive care unit, 
hemodynamic and respiratory parameters stabilised and 
the patient regained renal function. Moreover, platelet 
count normalized (Fig. 3). Due to essential repetitive sur-
gical interventions, administration of Argatroban had to 
be continued for at least 38 days because of—compared 
to vitamin k inhibitor—better perioperative controllabil-
ity. Therapy with Argatroban was switched to Phenpro-
coumon (Marcoumar®) afterwards according to current 
bridging guidelines. The patient could be transferred to 
the normal ward and further rehabilitation.
Fig. 1 Status post recent amputation of the right leg; ongoing necro-
sis of the left leg despite amputation 5 days before.
Fig. 2 Acral necrotic spots.
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Discussion and evaluation
Although drug exposure was uneventful 2  years ago, 
administration of LMWH [Enoxaparin (Lovenox®)] 
resulted in a catastrophic clinical course of HIT II. 
Despite immediate diagnosis and adjustment to recom-
mended therapeutic anticoagulant regime, the progress 
of the disease led to amputation of both lower limbs. 
Potential causes of this catastrophic outcome are dis-
cussed below.
The immunological pathomechanism of HIT II is com-
plex and not yet fully elucidated. Immunoglobuline G 
(IgG) antibodies against platelet factor 4 (PF4)/heparin 
complexes play a major role in development of HIT II. 
PF4 on the one hand has pro- and anticoagulant function 
in haemostasis. Antibodies against PF4/heparin com-
plexes generate an activation of platelets with release of 
procoagulant microparticles and increased generation of 
thrombin leading to thrombocytopenia based on plate-
let consumption within thrombotic formations and life-
threatening arterial and venous thromboembolic events 
(Dasararaju et  al. 2013; Linkins et  al. 2012; Greinacher 
et al. 2010).
On the other hand PF4 is also involved in inflammatory 
processes due to its immune-modulating effects (Pilatova 
et al. 2013). Therefore, gram negative bacterial infection 
and trauma—which are associated with an up-regulated 
overall immune system—have been discussed as priming 
factors to increase the risk of HIT II (Krauel et al. 2012).
There is evidence, that in obese patients lipotoxicity 
and cytokine dysregulation create a state of low-grade 
systemic inflammatory response (SIRS) comparable to 
gram negative sepsis (Cave et al. 2008). Adipocytes trig-
ger inflammatory pathways that lead to chronic increased 
levels of cytokines (e.g. TNFα, CCL 2, IL-6, IL-1β). Toll-
like-receptors (TLRs) of the innate immune system are 
activated as well (Gregor and Hotamisligil 2011). In the 
reported case an obese patient was exposed to major 
surgical trauma. Chronic inflammatory state and trauma 
as a second hit possibly contributed to the onset of HIT 
II. To the best of our knowledge, data from randomised, 
controlled trials confirming this hypothesis are missing 
so far.
According to the patient`s medical history he under-
went administration of Enoxaparin 2 years earlier in the 
context of surgical intervention of his shoulder. It remains 
speculative, if antibodies of a previous subclinical HIT 
could have caused the recurrence of the disease and if 
routinely performed monitoring of platelet count would 
have allowed diagnosis prior to clinical manifestation.
Reviewing current literature there is no evidence of 
remaining HIT antibodies 2  years after the administra-
tion of LMWH. Moreover, patients who are re-exposed 
to LMWH usually develop “early onset thrombocytope-
nia” (<5  days) due to prior immune response (Linkins 
et al. 2012; Lubenow et al. 2002). This was not the case in 
our patient who presented with new onset of thrombo-
cytopenia on day eight after surgery. Referring to data of 
Lubenov and colleagues, patients with a previous expo-
sure to heparin more than 3  months earlier had a time 
pattern of onset of thrombocytopenia indistinguishable 
from patients having had their initial exposure to hepa-
rin (Lubenow et al. 2002). This fact can be explained by 
the unique transient character of IgG antibodies in HIT 
II with a medium time to disappearance of 50–80  days 
(Lubenow et  al. 2002). Upon administration of LMWH 
monitoring of platelet count should be performed daily 
starting on day one in patients who underwent prior 
treatment with heparin or LMWH within 3  months. In 
all other patients measuring platelet count earliest on day 
five is sufficient (Linkins et al. 2012). Furthermore, there 
is evidence of thrombocytopenia in patients undergoing 
hip surgery within the first two postoperative days due to 
reasons not related to HIT (Lubenow et al. 2002).
In the reported case clinical and laboratory findings 
led to immediate initiation of evidence based therapy. 
Following the current ACCP guidelines Argatroban 
(Argatra®)—a hepatobiliary eliminated direct throm-
bin inhibitor—is recommended as an alternative antico-
agulant for therapy of HIT II (grade 1C). (Linkins et  al. 
2012) Argatroban dosing should be monitored with acti-
vated partial thromboplastin time (aPTT). According 
to the manufacturer’s guide one should go for a 1.5–3 
fold increase of the aPTT basic level. Due to transient 
impaired liver function, septic status and repetitive surgi-
cal interventions during the first days, aiming for recom-
mended aPTT levels was contraindicated with regard to 
increased bleeding risk in our patient. There is evidence 
of safely performed reduction of dose rates in critically 
Fig. 3 Postoperative platelet count plotted against aPTT levels.
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ill patients (Saugel et al. 2010; Link et al. 2009). In addi-
tion to closely performed monitoring of aPTT levels we 
quantified clearance of indocyanine green (ICG) to assess 
hepatic function as mentioned by Link et  al. (2009). 
ICG-PDR (ICG-plasma disappearance rate) levels were 
PDR 4.8 %/min and R15 48.7 %. However, we could not 
achieve significant increase in platelet count until aPTT 
levels reached the upper bound of the recommended lev-
els (Fig. 3). Considering that the magnitude of thrombo-
cytopenia correlates with thrombotic risk it seems, that 
an increase in platelet count represents effective dosage 
of Argatroban reflecting the breakdown of the vicious 
circle of consumption of IgG-coated platelets within 
thrombotic formations. (Greinacher et al. 2010).
Conclusion
Administration of LMWH in order to prevent from 
thromboembolic events can result in HIT II despite prior 
uneventful drug administration.
Except for immediate diagnosis, only consequent anti-
coagulation can stop the course of the disease. Hence, 
interdisciplinary awareness is inevitable for early diagno-
sis and accurate therapy to prevent from a catastrophic 
clinical course.
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